Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07168213

Comparison of Two SpO2 Targets With Two Different Oximeters - Impact on FiO2 During Nasal High Flow Oxygen Therapy

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
30 (estimated)
Sponsor
Laval University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Several factors can influence oxygenation monitoring and respiratory support through oxygen therapy: the type of oximeter used, skin pigmentation, and the oxygenation target. It is essential to have an accurate measurement of SpO2 in order to optimize the flow of oxygen or FiO2 administered to patients. The question arises as to the impact of these confounding factors on the FiO2 set during high-flow nasal oxygen therapy. The aim of the study is to evaluate the impact of the oxygenation target and the oximeter used on FiO2 in patients receiving high-flow nasal oxygen therapy.

Detailed description

The oximeters evaluated will be the Nonin (Plymouth, MN) and the Philips (Eindhoven, Netherlands). Two SpO2 targets will be evaluated: 90% and 94%. A total of four 10-minute periods will be performed in randomized order: Nonin 90, Nonin 94, Philips 90, and Philips 94. At the end of each 10-minute period, arterial gas will be collected through the arterial catheter.

Conditions

Interventions

TypeNameDescription
DEVICEManual FiO2 titration with Philips oximeter (SpO2 target 90%)FiO2 titration to reach the SpO2 target (set at 90%) with Philips oximeter
DEVICEManual FiO2 titration with Nonin oximeter (SpO2 target 90%)FiO2 titration to reach the SpO2 target (set at 90%) with Nonin oximeter
DEVICEManual FiO2 titration with Philips oximeter (SpO2 target 94%)FiO2 titration to reach the SpO2 target (set at 94%) with Philips oximeter
DEVICEManual FiO2 titration with Nonin oximeter (SpO2 target 94%)FiO2 titration to reach the SpO2 target (set at 94%) with Nonin oximeter

Timeline

Start date
2025-10-21
Primary completion
2027-06-01
Completion
2027-12-01
First posted
2025-09-11
Last updated
2026-03-09

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT07168213. Inclusion in this directory is not an endorsement.